11/22/2011

Celgene said a Swiss regulator approved blood cancer drug Revlimid as a treatment alternative for patients with myelodysplastic syndrome, a blood disorder that often leads to anemia and a need for regular blood transfusions. Revlimid is used mostly to treat multiple myeloma.

Related Summaries